Screener
Veracyte VCYT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 80 | 79 |
| Additional paid-in capital | 1,701,470 | 1,695,339 |
| Accumulated deficit | (348,923) | (377,630) |
| Accumulated other comprehensive loss | (8,221) | (8,212) |
| Total stockholders’ equity | 1,344,406 | 1,309,576 |
| Total liabilities and stockholders’ equity | $1,436,400 | $1,406,019 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's total equity?
- Veracyte (VCYT) reported total equity of $1.34B in Q1 2026.
- How has Veracyte's total equity changed year-over-year?
- Veracyte's total equity increased by 12.5% year-over-year, from $1.19B to $1.34B.
- What is the long-term trend for Veracyte's total equity?
- Over 5 years (2020 to 2025), Veracyte's total equity has grown at a 25.5% compound annual growth rate (CAGR), from $421.23M to $1.31B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Veracyte's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude